Kura Oncology Inc (NASDAQ:KURA) traded up 6.5% during trading on Friday . The company traded as high as $14.09 and last traded at $13.84, 302,100 shares changed hands during trading. An increase of 13% from the average session volume of 267,383 shares. The stock had previously closed at $12.99.
A number of equities research analysts have recently commented on the company. JMP Securities reiterated a “market outperform” rating and set a $22.00 target price on shares of Kura Oncology in a research note on Thursday, September 5th. ValuEngine cut Kura Oncology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 5th. Wedbush restated a “positive” rating on shares of Kura Oncology in a research note on Wednesday, September 4th. Leerink Swann set a $27.00 price objective on Kura Oncology and gave the company a “buy” rating in a research note on Saturday, June 15th. Finally, Deutsche Bank initiated coverage on Kura Oncology in a research note on Thursday, July 18th. They issued a “buy” rating and a $28.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $27.10.
The stock has a 50 day moving average of $15.44 and a 200-day moving average of $17.02. The company has a quick ratio of 23.50, a current ratio of 23.50 and a debt-to-equity ratio of 0.03.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.03. On average, equities analysts anticipate that Kura Oncology Inc will post -1.61 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd bought a new stake in Kura Oncology in the 2nd quarter valued at about $25,000. Meeder Asset Management Inc. increased its position in shares of Kura Oncology by 164.9% during the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock valued at $38,000 after buying an additional 1,204 shares during the period. Bank of Montreal Can increased its position in shares of Kura Oncology by 82,066.7% during the second quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock valued at $49,000 after buying an additional 2,462 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Kura Oncology by 599.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after buying an additional 2,420 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of Kura Oncology during the second quarter valued at about $59,000. Institutional investors and hedge funds own 85.47% of the company’s stock.
About Kura Oncology (NASDAQ:KURA)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.